Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders

The QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.